Vasen, H.F. et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62, 812–823 (2013).
Umar, A. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96, 261–268 (2004).
van Oers, J.M. et al. PMS2 endonuclease activity has distinct biological functions and is essential for genome maintenance. Proc. Natl. Acad. Sci. USA 107, 13384–13389 (2010).
Win, A.K. et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J. Natl. Cancer Inst. 104, 1363–1372 (2012).
Buerki, N. et al. Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosom. Cancer 51, 83–91 (2012).
Scott, R.J. et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am. J. Hum. Genet. 68, 118–127 (2001).
Grindedal, E.M. et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol. Biomarkers Prev. 18, 2460–2467 (2009).
Win, A.K. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol. 30, 958–964 (2012).
Järvinen, H.J. et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J. Clin. Oncol. 27, 4793–4797 (2009).
Plon, S.E. et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29, 1282–1291 (2008).
Tavtigian, S.V., Greenblatt, M.S., Goldgar, D.E. & Boffetta, P. Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Hum. Mutat. 29, 1261–1264 (2008).
Richards, C.S. et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet. Med. 10, 294–300 (2008).
Easton, D.F. et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer–predisposition genes. Am. J. Hum. Genet. 81, 873–883 (2007).
Goldgar, D.E. et al. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum. Mutat. 29, 1265–1272 (2008).
Goldgar, D.E. et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet. 75, 535–544 (2004).
Thompson, B.A. et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. Hum. Mutat. 34, 200–209 (2013).
Spurdle, A.B., Couch, F.J., Hogervorst, F.B., Radice, P. & Sinilnikova, O.M. Prediction and assessment of splicing alterations: implications for clinical testing. Hum. Mutat. 29, 1304–1313 (2008).
Greenblatt, M.S. et al. Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum. Mutat. 29, 1273–1281 (2008).
Plazzer, J.P. et al. The InSiGHT database: utilizing 100 years of insights into Lynch syndrome. Fam. Cancer 12, 175–180 (2013).
Peltomäki, P. & Vasen, H. Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis. Markers 20, 269–276 (2004).
Peltomäki, P. & Vasen, H.F. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113, 1146–1158 (1997).
Ou, J. et al. Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes. Hum. Mutat. 28, 1047–1054 (2007).
Woods, M.O. et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Hum. Mutat. 28, 669–673 (2007).
Giardine, B. et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat. Genet. 43, 295–301 (2011).
Fox, B.I. et al. Developing an expert panel process to refine health outcome definitions in observational data. J. Biomed. Inform. 46, 795–804 (2013).
Kohonen-Corish, M.R. et al. Deciphering the colon cancer genes—report of the InSiGHT–Human Variome Project Workshop, UNESCO, Paris 2010. Hum. Mutat. 32, 491–494 (2011).
Thompson, D., Easton, D.F. & Goldgar, D.E. A full-likelihood method for the evaluation of causality of sequence variants from family data. Am. J. Hum. Genet. 73, 652–655 (2003).
Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135, 419–428 (2008).
Baglietto, L. et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J. Natl. Cancer Inst. 102, 193–201 (2010).
Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. J. Am. Med. Assoc. 305, 2304–2310 (2011).
Mangold, E. et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. Int. J. Cancer 116, 692–702 (2005).
Barnetson, R.A. et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med. 354, 2751–2763 (2006).
Patrinos, G.P. et al. Microattribution and nanopublication as means to incentivize the placement of human genome variation data into the public domain. Hum. Mutat. 33, 1503–1512 (2012).
Thompson, B.A. et al. Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum. Mutat. 34, 255–265 (2013).
Vallée, M.P. et al. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum. Mutat. 33, 22–28 (2012).
Drost, M. et al. A rapid and cell-free assay to test the activity of Lynch syndrome–associated MSH2 and MSH6 missense variants. Hum. Mutat. 33, 488–494 (2012).
Heinen, C.D. & Juel Rasmussen, L. Determining the functional significance of mismatch repair gene missense variants using biochemical and cellular assays. Hered. Cancer Clin. Pract. 10, 9 (2012).
Couch, F.J. et al. Assessment of functional effects of unclassified genetic variants. Hum. Mutat. 29, 1314–1326 (2008).
Rasmussen, L.J. et al. Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present and future. Hum. Mutat. 33, 1617–1625 (2012).
Leenen, C.H. et al. Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic PMS2 germline mutations. Clin. Genet. 80, 558–565 (2011).
Mead, L.J. et al. Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes. Clin. Cancer Res. 13, 2865–2869 (2007).
Plaschke, J. et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J. Clin. Oncol. 22, 4486–4494 (2004).
Wu, Y. et al. Association of hereditary nonpolyposis colorectal cancer–related tumors displaying low microsatellite instability with MSH6 germline mutations. Am. J. Hum. Genet. 65, 1291–1298 (1999).
You, J.F. et al. Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br. J. Cancer 103, 1840–1845 (2010).
Spurdle, A.B. et al. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J. Med. Genet. 49, 525–532 (2012).
Xie, J. et al. An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy. Cancer Prev. Res. (Phila.) 3, 1409–1416 (2010).
Kosinski, J., Hinrichsen, I., Bujnicki, J.M., Friedhoff, P. & Plotz, G. Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair. Hum. Mutat. 31, 975–982 (2010).
Takahashi, M. et al. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res. 67, 4595–4604 (2007).
Hinrichsen, I. et al. Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis. Clin. Cancer Res. 19, 2432–2441 (2013).
Wildeman, M., van Ophuizen, E., den Dunnen, J.T. & Taschner, P.E. Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. Hum. Mutat. 29, 6–13 (2008).
Arnold, S. et al. Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum. Mutat. 30, 757–770 (2009).
Spurdle, A.B. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Curr. Opin. Genet. Dev. 20, 315–323 (2010).
Wimmer, K. & Etzler, J. Constitutional mismatch repair–deficiency syndrome: have we so far seen only the tip of an iceberg? Hum. Genet. 124, 105–122 (2008).
1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).
ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).